<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Headache Pain</journal-id><journal-id journal-id-type="iso-abbrev">J Headache Pain</journal-id><journal-title-group><journal-title>The Journal of Headache and Pain</journal-title></journal-title-group><issn pub-type="ppub">1129-2369</issn><issn pub-type="epub">1129-2377</issn><publisher><publisher-name>Springer Milan</publisher-name><publisher-loc>Milan</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5815979</article-id><article-id pub-id-type="publisher-id">821</article-id><article-id pub-id-type="doi">10.1186/s10194-017-0821-3</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>PACAP38 in human models of primary headaches</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ashina</surname><given-names>H&#x000e5;kan</given-names></name><address><email>ashinajudo@yahoo.dk</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Guo</surname><given-names>Song</given-names></name><address><email>song60887727@gmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Vollesen</surname><given-names>Anne L. H.</given-names></name><address><email>luisevollesen@gmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Ashina</surname><given-names>Messoud</given-names></name><address><phone>(+45) 38 63 33 85</phone><email>ashina@dadlnet.dk</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0674 042X</institution-id><institution-id institution-id-type="GRID">grid.5254.6</institution-id><institution>Department of Neurology, Danish Headache Center, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, </institution><institution>University of Copenhagen, </institution></institution-wrap>Copenhagen, Denmark </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>11</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>11</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>18</volume><issue>1</issue><elocation-id>110</elocation-id><history><date date-type="received"><day>9</day><month>9</month><year>2017</year></date><date date-type="accepted"><day>14</day><month>11</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">To review the role of PACAP38 in human models of primary headaches, discuss possible mechanisms of PACAP38-induced migraine, and outline future directions.</p></sec><sec><title>Discussion</title><p id="Par2">Experimental studies have established PACAP38 as a potent pharmacological &#x0201c;trigger&#x0201d; molecule of migraine-like attacks. These studies have also revealed a heterogeneous PACAP38 migraine response in migraine without aura patients. In addition, findings from brain imaging studies have demonstrated neuronal and vascular changes in migraine patients both ictally and interictally after PACAP38 infusion.</p></sec><sec><title>Conclusion</title><p id="Par3">Human migraine models have shed light on the importance of PACAP38 in the pathophysiology of primary headaches. These studies have also pointed to the PAC<sub>1</sub> receptor and the PACAP38 molecule itself as target sites for drug testing. Future research should seek to understand the mechanisms underlying PACAP38-induced migraine. The results from an ongoing proof of concept randomized clinical trial may reveal the therapeutic potential of anti-PAC<sub>1</sub> receptor antibodies for migraine prevention.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>PACAP38</kwd><kwd>Human provocation models</kwd><kwd>Primary headaches</kwd><kwd>PAC<sub>1</sub></kwd><kwd>Migraine</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003554</institution-id><institution>Lundbeckfonden</institution></institution-wrap></funding-source><award-id>R155-2014-171</award-id><principal-award-recipient><name><surname>Ashina</surname><given-names>Messoud</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par21">Much research effort has been devoted to studying the pathophysiology of primary headaches using human experimental models, which have led to the discovery of novel headache-eliciting signaling pathways and new drug targets [<xref ref-type="bibr" rid="CR1">1</xref>]. In this context, pituitary adenylate cyclase-activating polypeptide (PACAP) has over the past decade emerged as a key signaling molecule implicated in migraine [<xref ref-type="bibr" rid="CR2">2</xref>] and possibly also in cluster headache [<xref ref-type="bibr" rid="CR3">3</xref>].</p><p id="Par22">PACAP belongs to the glucagon/secretin superfamily of peptides together with vasoactive intestinal polypeptide (VIP) [<xref ref-type="bibr" rid="CR4">4</xref>] and exists in two bioactive forms: a 38 amino acid form (PACAP38) and a truncated 27 amino acid form (PACAP27) [<xref ref-type="bibr" rid="CR5">5</xref>]. PACAP38 is present in first-order neurons in the trigeminal ganglion [<xref ref-type="bibr" rid="CR6">6</xref>], second-order neurons in the trigeminal nucleus caudalis (TNC) [<xref ref-type="bibr" rid="CR7">7</xref>], and dorsal horn of the human spinal cord [<xref ref-type="bibr" rid="CR8">8</xref>]. In addition, PACAP38 has also been identified in the otic and sphenopalatine ganglia [<xref ref-type="bibr" rid="CR9">9</xref>], as well as in the cerebral cortex, cerebellum, brain stem and hypothalamus [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par23">The effect of PACAP38 is mediated through three G-protein coupled receptors (PAC<sub>1</sub>, VPAC<sub>1&#x02013;2</sub>) [<xref ref-type="bibr" rid="CR11">11</xref>], two of which (VPAC<sub>1&#x02013;2</sub>) hold equal affinity for PACAP38 and VIP, while the PAC<sub>1</sub> receptor has a much higher affinity for PACAP38 [<xref ref-type="bibr" rid="CR12">12</xref>]. The distribution of all three receptors has been documented in trigeminal, otic and superior cervical ganglia [<xref ref-type="bibr" rid="CR13">13</xref>], as well as in cerebral and meningeal arteries [<xref ref-type="bibr" rid="CR14">14</xref>]. Upon activation, all receptors cause downstream production of cyclic adenosine monophosphate (cAMP) through adenylate cyclase (AC) stimulation [<xref ref-type="bibr" rid="CR15">15</xref>]. Studies have reported that the VPAC<sub>1&#x02013;2</sub> receptors play a role in vasodilation and mast cell degranulation [<xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>], whereas one study in rats implicated the PAC<sub>1</sub> receptor in pro-nociceptive transmission [<xref ref-type="bibr" rid="CR21">21</xref>].</p><p id="Par24">The headache-inducing effect of PACAP38 has been extensively studied in both healthy volunteers and migraine without aura (MO) patients. This has sparked an interest in pursuing specific treatment options targeting the PACAP38 molecule [<xref ref-type="bibr" rid="CR22">22</xref>] or its PAC<sub>1</sub> receptor [<xref ref-type="bibr" rid="CR23">23</xref>]. Future randomized clinical trials (RCTs) will fully uncover whether PACAP38 or PAC<sub>1</sub> receptor blockade could be a promising new approach in treating primary headaches.</p><p id="Par25">In this review, we focus on human headache models using PACAP38 as a pharmacological &#x0201c;trigger&#x0201d; of migraine-like attacks. We then consider methodological aspects and limitations. Finally, we outline future perspectives and the therapeutic potential of anti-PACAP38 treatment to address unmet patient needs.</p></sec><sec id="Sec2"><title>PACAP38 migraine models</title><p id="Par26">Birk et al. [<xref ref-type="bibr" rid="CR24">24</xref>] for the first time systematically investigated PACAP38-induced headache and cerebral hemodynamics in 12 healthy volunteers. In this and the following described studies, healthy volunteers were identified as subjects who had no prior history of migraine and no first-degree relatives suffering from migraine. Ten out of 12 participants (83%) reported mild to moderate headache following PACAP38 infusion over 20&#x000a0;min, while no effect was observed on regional cerebral blood flow. There was a minor dilation of the middle cerebral artery (MCA) recorded by a transcranial Doppler (TCD) after PACAP38 infusion. However, certain limitations of the TCD method should be acknowledged. The TCD method assesses MCA velocity, which is dependent on the blood flow and the cross-sectional area of the artery. To interpret reduced velocity as arterial dilation, it requires that cerebral blood flow is constant despite heart rate variability and different angles of insonation. A more detailed description of methodological considerations on arterial measurements by TCD has recently been reviewed [<xref ref-type="bibr" rid="CR25">25</xref>]. In healthy volunteers, the dose-response to 5, 10, 15, and 20&#x000a0;pmol kg<sup>&#x02212;1</sup>&#x000a0;min<sup>&#x02212;1</sup> was investigated in three participants [<xref ref-type="bibr" rid="CR24">24</xref>]. In all three cases the infusion was aborted after 10&#x000a0;pmol kg<sup>&#x02212;1</sup>&#x000a0;min<sup>&#x02212;1</sup> due to 40&#x02013;50% increases in heart rate &#x02013; probably compensatory to the vasodilating effect of PACAP38. Following these observations, which have recently been confirmed in a dose-response study [<xref ref-type="bibr" rid="CR26">26</xref>]; a dose of 10&#x000a0;pmol kg<sup>&#x02212;1</sup>&#x000a0;min<sup>&#x02212;1</sup> is considered the optimal dose for experimental provocation studies.</p><p id="Par27">Given that experimentally provoked attacks are not spontaneous according to the International Headache Society (IHS) criteria [<xref ref-type="bibr" rid="CR27">27</xref>], different criteria for experimentally induced migraine attacks have been introduced [<xref ref-type="bibr" rid="CR28">28</xref>]. The provoked migraine attacks should either fulfill IHS criteria C and D for MO [<xref ref-type="bibr" rid="CR25">25</xref>] or mimic the usual migraine attack experienced by the patient and subsequent response to treatment with acute rescue medication [<xref ref-type="bibr" rid="CR28">28</xref>]. To investigate the migraine-inducing effects of intravenous PACAP38 infusion, Schytz et al. [<xref ref-type="bibr" rid="CR29">29</xref>] performed a double-blind, placebo-controlled crossover studies in 12 healthy volunteers and 12 MO patients. The authors hypothesized that PACAP38 infusion would induce headache in controls and migraine-like attacks in MO patients. All controls reported headache after PACAP38 infusion, while two controls also experienced migraine-like attacks. In MO patients, 7 out of 12 subjects (58%) reported migraine-like attacks after PACAP38 infusion compared with zero after placebo. Interestingly, the median time to peak headache score (4&#x000a0;h, range 0&#x02013;12&#x000a0;h) in MO patients following PACAP38 provocation was similar to those reported in calcitonin gene-related peptide (CGRP) (5&#x000a0;h, range 2-9&#x000a0;h) and glyceryl trinitrate (GTN) (5.5&#x000a0;h, range 3&#x02013;10&#x000a0;h) provocation studies [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. Moreover, the authors assessed the vascular effects of PACAP38 infusion on the MCA by TCD and the superficial temporal artery (STA) by dermascan ultrasonography during the hospital phase of the study (0-2&#x000a0;h post infusion) [<xref ref-type="bibr" rid="CR29">29</xref>]. In MO patients, PACAP38 infusion caused a modest MCA dilation of 9.5% compared to baseline, while a more marked dilation of 37.5% was found in the STA. This study yielded two important findings. First, PACAP38 induced migraine-like attacks in 58% of MO patients, while no attacks were reported after placebo. Secondly, prolonged cranial artery dilation suggested a possible role of vascular mechanisms in PACAP38-induced migraine.</p><p id="Par28">Magnetic resonance angiography (MRA) constitutes a superior method for measuring vessel diameter compared to TCD and provides more precise measurements of circumferential arterial changes [<xref ref-type="bibr" rid="CR32">32</xref>]. All of the described provocation studies using TCD and MRA only assessed vascular effects in the middle meningeal artery (MMA), STA, and MCA [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Using MRA, a double-blind, placebo-controlled study investigated the effect of PACAP38 infusion on the MCA and MMA in healthy volunteers [<xref ref-type="bibr" rid="CR33">33</xref>]. The MMA was selected because it is the main artery supplying the dura mater and one previous study demonstrated MMA (but not MCA) involvement in CGRP-induced headache in healthy volunteers [<xref ref-type="bibr" rid="CR35">35</xref>]. The major finding of the MRA study [<xref ref-type="bibr" rid="CR33">33</xref>] was that PACAP infusion caused a long-lasting dilation (&#x0003e; 5&#x000a0;h) of the MMA co-occurring with headache, while no effect was found on the MCA circumference. In addition, subcutaneous injection of sumatriptan reversed the MMA dilation and headache, whereas the MCA circumference was unaltered. It is possible that PACAP38 does not reach its receptors on the smooth muscle cells in the MCA. In support, in vitro studies [<xref ref-type="bibr" rid="CR36">36</xref>] reported a vasodilatory effect of PACAP38 on the rat and human MCA when applied abluminally but <italic>not</italic> luminally. The question is whether MMA dilation with co-occurring headache following PACAP38&#x000a0;infusion and the subsequent MMA constriction with&#x000a0;co-occurring headache relief following sumatriptan reflect the importance of the MMA in migraine generation and cessation. It should be noted that sumatriptan is a 5-HT1B/1D receptor agonist that was originally developed as vasoconstrictor acting through receptor binding on cranial vessels [<xref ref-type="bibr" rid="CR37">37</xref>]. However, its exact mechanism of action in relation to migraine remains a highly debated topic [<xref ref-type="bibr" rid="CR38">38</xref>]. In healthy volunteers, subcutaneous injection of sumatriptan caused constriction of the STA, MMA, and MCA [<xref ref-type="bibr" rid="CR39">39</xref>]. However, the same authors found a significantly smaller intracerebral arterial constriction compared with the constriction of extracerebral arteries &#x02013; suggesting a primarily peripheral site of action for triptans. In the context of human provocation studies, subcutaneous injection of sumatriptan caused co-occurring MMA constriction and amelioration of migraine-like attacks following both PACAP38 [<xref ref-type="bibr" rid="CR33">33</xref>] and CGRP [<xref ref-type="bibr" rid="CR40">40</xref>] infusion. In both provocation studies [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR40">40</xref>], no sumatriptan effect was found on the MCA circumference.</p><p id="Par29">An interesting aspect to consider is that even though VIP belongs to the same family of peptides as PACAP38 [<xref ref-type="bibr" rid="CR41">41</xref>], it does not induce migraine attacks in MO patients [<xref ref-type="bibr" rid="CR42">42</xref>]. VIP infusion only induced dilation of cranial arteries and mild headache [<xref ref-type="bibr" rid="CR42">42</xref>]. To further examine this issue, one MRA study investigated the response to intravenous infusion of PACAP38 or VIP in MO patients [<xref ref-type="bibr" rid="CR34">34</xref>]. Sixteen out of 22 patients (73%) reported delayed migraine-like attacks following PACAP38 infusion, whereas only 4 out of 22 (18%) did so after VIP infusion. Moreover, this study found that both PACAP38 and VIP induced STA and MMA dilation, while the MCA remained unaffected. The PACAP38-induced vasodilation was longer-lasting (&#x0003e; 2&#x000a0;h) than the VIP-induced vasodilation which normalized after 2&#x000a0;h. Interestingly, there was no difference in arterial circumference between the pain and non-pain side during PACAP38-induced migraine-like attacks in 9 patients. Subcutaneous injection of sumatriptan reduced headache intensity and caused constriction of only the extracranial arteries. Another key finding from this study was that plasma levels of PACAP38 were elevated in MO patients who developed migraine-like attacks compared to those who did not 60&#x000a0;min after PACAP38 infusion. Since plasma PACAP38 has&#x000a0;a half-life of 3.5&#x000a0;min [<xref ref-type="bibr" rid="CR24">24</xref>], a complete clearance of exogenous PACAP38 is expected 60&#x000a0;min after the start of infusion. To explain this, the authors suggested three possible mechanisms [<xref ref-type="bibr" rid="CR34">34</xref>]: 1) impaired elimination; 2) endogenous release; 3) de novo synthesis. However, when the data from this study [<xref ref-type="bibr" rid="CR40">40</xref>] was later pooled with data from a second study from the same research group [<xref ref-type="bibr" rid="CR43">43</xref>] to increase power and sample size, there was no difference in pre-ictal PACAP38 plasma levels between patients who developed migraine-like attacks (<italic>n</italic>&#x02009;=&#x02009;39) compared to those who did not (<italic>n</italic>&#x02009;=&#x02009;15). To our knowledge, no study has investigated the underlying mechanisms of PACAP38-induced prolonged vasodilation.</p><p id="Par30">A resting-state functional magnetic resonance imaging (fMRI) study examined the involvement of specific changes in cerebral network connectivity before and during PACAP38-induced migraine-like attacks in MO patients [<xref ref-type="bibr" rid="CR44">44</xref>]. VIP was used as active placebo. Resting state fMRI is a method to evaluate regional interactions in cerebral connectivity when a subject is not performing an explicit task. Patients were scanned 30&#x000a0;min, 130&#x000a0;min, and 310&#x000a0;min after PACAP38-infusion, unless they reported migraine-like attacks. In the event of migraine-like attacks, immediate scans were performed. The study found abnormal cerebral connectivity in all the investigated cerebral networks (salience, sensorimotor, and default mode) at the onset of migraine-like attacks after PACAP38 infusion when compared to outside of the attacks [<xref ref-type="bibr" rid="CR44">44</xref>]. No alterations in cerebral connectivity were found following VIP infusion. These findings are interesting because those three networks have been implicated in the processing of nociceptive and emotional signals [<xref ref-type="bibr" rid="CR45">45</xref>&#x02013;<xref ref-type="bibr" rid="CR48">48</xref>]. To solidify the importance of these findings, the authors suggested that a similar experiment should be conducted before and at the early phase of spontaneous migraine attacks.</p><p id="Par31">One provocation study has also examined the incidence of premonitory symptoms induced by intravenous PACAP38 administration in MO patients [<xref ref-type="bibr" rid="CR49">49</xref>]. Premonitory symptoms occur hours to 2&#x000a0;days prior to the migraine attack [<xref ref-type="bibr" rid="CR28">28</xref>] and most commonly present themselves as unusual fatigue, neck stiffness, and poor concentration. It has previously been reported that 36% of migraine patients experience premonitory symptoms following GTN infusion [<xref ref-type="bibr" rid="CR50">50</xref>]. Following PACAP38-infusion [<xref ref-type="bibr" rid="CR49">49</xref>], 72% and 48% of the patients experienced migraine-like attacks and premonitory symptoms, respectively. Interestingly, CGRP did not induce premonitory symptoms in the same group of patients. In addition, there was no difference of premonitory symptoms in patients who developed attacks versus those who did not. These findings are interesting because premonitory symptoms are considered a marker of CNS involvement. However, the study did not include a healthy control group or placebo-treated patients. Therefore, we cannot exclude that the observed association between PACAP38 infusion and premonitory symptoms could be due to substance-related side effects.</p><p id="Par32">As we reflect on the headache-inducing capabilities of PACAP38, it is interesting that some MO patients develop migraine-like attacks while others do not. The question is whether fluctuating susceptibility could be due to genetic variations among migraine patients. Genetic studies have documented that genetic enrichment of certain risk factor genes constitute a predisposition to developing migraine [<xref ref-type="bibr" rid="CR51">51</xref>&#x02013;<xref ref-type="bibr" rid="CR53">53</xref>]. To address this issue, one study [<xref ref-type="bibr" rid="CR54">54</xref>] stratified patients into two groups: one group with high family load (&#x02265; 2 first-degree relatives with MO) and one group with low family load (&#x02264; 1 first-degree relatives with MO). In addition, genotyped patients were stratified based on risk allele status. This study revealed no association of hypersensitivity to migraine following PACAP38 administration based on family load and migraine-associated risk allele status in 32 genotyped MO patients.</p></sec><sec id="Sec3"><title>Possible mechanisms of PACAP38-induced migraine</title><p id="Par33">Several possible mechanisms on the migraine-inducing effect of PACAP38 have been suggested: vasodilatation via cAMP, mast cell degranulation, parasympathetic involvement, activation of sensory afferents by the cAMP-signaling pathway or via the PAC<sub>1</sub> receptor, and central effects.</p><sec id="Sec4"><title>Vasodilation via cAMP</title><p id="Par34">PACAP38 is a powerful dilator of cerebral arteries [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR33">33</xref>] and its effect is mediated through a cAMP-dependent signaling pathway [<xref ref-type="bibr" rid="CR15">15</xref>]. In relation to migraine, one human experimental study provided evidence for cAMP upregulation in migraine induction in MO patients after cilostazol (phosphodiesterase 5 inhibitor) administration [<xref ref-type="bibr" rid="CR28">28</xref>]. Interestingly, cilostazol is known to produce a long-lasting dilation of cerebral arteries [<xref ref-type="bibr" rid="CR55">55</xref>] and PACAP38 induces long-lasting MMA-dilation (&#x0003e; 2&#x000a0;h) [<xref ref-type="bibr" rid="CR34">34</xref>]. To what extent the long-lasting MMA-dilation contributes to PACAP38-induced migraine remains unknown.</p></sec><sec id="Sec5"><title>Mast cell degranulation</title><p id="Par35">Another interesting aspect to consider is the role of mast cell degranulation in PACAP38-induced migraine. Mast cells are found throughout the human organism and play an important role in the immediate response to hypersensitivity reactions [<xref ref-type="bibr" rid="CR56">56</xref>]. Upon activation, mast cells release soluble mediators (e.g. histamine, TNF-&#x003b1;, and tryptase) into the circulation. Interestingly, histamine induces migraine-like attacks in 70% of MO patients [<xref ref-type="bibr" rid="CR57">57</xref>]. Furthermore, mepyramine (a histamine H<sub>1</sub> receptor blocker) pretreatment abolished both immediate and delayed histamine-induced migraine-like attacks in the same group of MO patients [<xref ref-type="bibr" rid="CR57">57</xref>]. In relation to PACAP38, one in vitro study found that PACAP38 induced mast cell degranulation in dural and peritoneal mast cells in rats [<xref ref-type="bibr" rid="CR58">58</xref>]. Furthermore, PACAP38-induced MMA dilation was abolished in both mast cell depleted and antihistamine pretreated rats [<xref ref-type="bibr" rid="CR59">59</xref>]. Therefore, the authors suggested that mast cell mediated histamine release was implicated in PACAP38-induced MMA-dilation [<xref ref-type="bibr" rid="CR59">59</xref>]. In rats, mast cell degranulation activates and sensitizes meningeal dural afferents [<xref ref-type="bibr" rid="CR60">60</xref>]. Interestingly, PACAP38 has a more potent degranulatory effect on dural mast cells in rats compared with PACAP27 and VIP [<xref ref-type="bibr" rid="CR58">58</xref>]. Thus, it seems conceivable that the effect of PACAP38 on mast cell degranulation is primarily mediated through the PAC<sub>1</sub> receptor because VIP had a lesser effect on mast cells. However, the same study [<xref ref-type="bibr" rid="CR58">58</xref>] also found no effect of PAC<sub>1</sub> receptor agonist (maxadilan) on mast cells, while PAC<sub>1</sub> receptor antagonism mediated mast cell degranulation. Thus, it could be speculated whether PACAP38 elicits its effect on mast cells through a distinct target from the PAC<sub>1</sub> receptor. In humans, PACAP38-associated flushing and heat-sensation terminated following anti-histamine treatment [<xref ref-type="bibr" rid="CR29">29</xref>]. It should, however, be noted that two human provocation studies collected peripheral plasma levels of inflammatory mast cell mediators (tumor necrosis factor alpha and tryptase) in MO patients after PACAP38 infusion [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. These studies found no changes in plasma tumor necrosis factor alpha and tryptase. Whether peripheral plasma changes reliably reflect cranial release of mast cell mediators remains unknown. Also, timing of collection might play a role in detecting altered peripheral plasma levels of mast cell mediators. Thus, mast cell degranulation cannot be completely dismissed as a mediator in the migraine-inducing mechanisms of PACAP38.</p></sec><sec id="Sec6"><title>PACAP38 in the parasympathetic system</title><p id="Par36">PACAP38 has been identified in both the sensory [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>] and parasympathetic system [<xref ref-type="bibr" rid="CR61">61</xref>]. The parasympathetic distribution of PACAP38 stems from the sphenopalatine and otic ganglia [<xref ref-type="bibr" rid="CR9">9</xref>], as well as from parasympathetic perivascular nerve fibers [<xref ref-type="bibr" rid="CR62">62</xref>]. It has been suggested that parasympathetic efferent fibers play a role in the trigeminovascular system by releasing neuropeptides, such as PACAP38, involved in nociceptive transmission [<xref ref-type="bibr" rid="CR63">63</xref>]. Interestingly, VIP is also present in both the sphenopalatine and otic ganglia [<xref ref-type="bibr" rid="CR64">64</xref>], but <italic>no</italic> VIP immunoreactivity has been found in the trigeminal ganglion [<xref ref-type="bibr" rid="CR65">65</xref>]. These data indicate that PACAP38 has two sites of origin unlike VIP: the parasympathetic system and the sensory system. In this context, it is also interesting that the PACAP and VIP molecules are parasympathetic biomarkers and both are less prominently expressed in the dura mater and trigeminal ganglion compared with CGRP, while being more prominently expressed in cerebral vessels [<xref ref-type="bibr" rid="CR66">66</xref>]. Therefore, the authors speculated that PACAP has a larger parasympathetic distribution and a minor sensory distribution. These data suggest PACAP38 might function primarily as a neuropeptide in parasympathetic pathways underlying migraine, while CGRP acts as a neuropeptide in sensory pathways underlying migraine. However, to what extent parasympathetic efferent fibers play a role in PACAP38-induced migraine remains a subject for further investigation.</p></sec><sec id="Sec7"><title>Activation of sensory afferents by the cAMP-signaling pathway or via the PAC<sub>1</sub> receptor</title><p id="Par37">In the sensory nervous system, PACAP38 is present in first-order neurons in the trigeminal ganglion [<xref ref-type="bibr" rid="CR6">6</xref>] and in second-order neurons in the TNC [<xref ref-type="bibr" rid="CR7">7</xref>]. All three PACAP38 receptors upregulate cAMP [<xref ref-type="bibr" rid="CR14">14</xref>] and PACAP38 receptors have been detected in both the trigeminal ganglion [<xref ref-type="bibr" rid="CR13">13</xref>] and TNC [<xref ref-type="bibr" rid="CR67">67</xref>]. In view of findings from human experimental data, migraine-like attacks after PACAP38 infusion could be explained by modulation of dural or extracranial trigeminal nociceptors outside of the BBB [<xref ref-type="bibr" rid="CR68">68</xref>]. The presence of all PACAP38 receptors has been identified in the vessel wall of human cerebral arteries [<xref ref-type="bibr" rid="CR13">13</xref>]. Hence, it could be speculated that PACAP38 upregulates intracellular cAMP in trigeminal nociceptors following PAC<sub>1</sub> receptor activation. This mechanism could possibly initiate a neurobiological cascade resulting in migraine attack development. Indeed, CGRP and cilostazol also upregulate intracellular cAMP [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>] and both are potent triggers of migraine-like attacks in MO patients [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR71">71</xref>]. In this context, it is interesting that elevated intracellular cAMP levels have been associated with activation of trigeminal neurons [<xref ref-type="bibr" rid="CR72">72</xref>] and meningeal nociceptors [<xref ref-type="bibr" rid="CR73">73</xref>]. Given that both PACAP38 and CGRP act on cell membrane receptors one would expect a similar median time to migraine onset after infusion. However, direct comparison of different groups of patients is problematic. To directly compare PACAP38 and CGRP migraine responses would require head to head comparison in the same group of patients. To date, this has not been investigated. One ongoing RCT is currently investigating the ability of CGRP blockade to prevent PACAP38-induced migraine [<xref ref-type="bibr" rid="CR74">74</xref>].</p></sec><sec id="Sec8"><title>PACAP38 and central effects</title><p id="Par38">It has been reported that PACAP38 is able to cross the BBB by a saturable transport mechanism [<xref ref-type="bibr" rid="CR75">75</xref>] and that 0.053% of PACAP38 passes the BBB after 5&#x000a0;min following intravenous infusion [<xref ref-type="bibr" rid="CR76">76</xref>]. Animal models have implicated PACAP38 in central nociceptive transmission [<xref ref-type="bibr" rid="CR77">77</xref>] and in rats intrathecal capsaicin elevated PACAP levels in the cerebrospinal fluid [<xref ref-type="bibr" rid="CR78">78</xref>]. Hence, spinal cord C-fibers might release PACAP upon activation. Therefore, PACAP38 might modulate nociceptive input through its PAC<sub>1</sub> receptor which is expressed on second-order trigeminal neurons [<xref ref-type="bibr" rid="CR7">7</xref>]. Furthermore, the hypothalamus contains the most abundant population of PACAP38-containing neurons [<xref ref-type="bibr" rid="CR79">79</xref>] and its activation has previously been associated with premonitory symptoms in GTN-provoked migraine attacks [<xref ref-type="bibr" rid="CR80">80</xref>]. Interestingly, MO patients reported premonitory symptoms after PACAP38 infusion [<xref ref-type="bibr" rid="CR49">49</xref>]. Yet, we do not have sufficient data to confirm or refute a central effect of PACAP38-induced migraine-like attacks.</p></sec></sec><sec id="Sec9"><title>Discussion and future perspectives</title><p id="Par39">The human experimental studies have demonstrated the potency of PACAP38 as a pharmacological &#x0201c;trigger&#x0201d; of migraine-like attacks [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]. Yet, there are several methodological limitations and aspects worth pointing out that should be optimized in future study designs. In the following, we will discuss: 1) Plasma PACAP38 as a biochemical marker in human experimental models; 2) heterogeneity of the PACAP38 response in MO patients; 3) MRA biomarkers of PACAP38-induced migraine-like attacks; 4) future experimental models using PACAP27.</p><sec id="Sec10"><title>PACAP38 as a biochemical marker</title><p id="Par40">In migraine patients, PACAP38 plasma levels have been measured during both spontaneous [<xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR82">82</xref>] and PACAP38-induced [<xref ref-type="bibr" rid="CR43">43</xref>] migraine attacks. Tuka et al. [<xref ref-type="bibr" rid="CR81">81</xref>] reported elevated ictal PACAP38 plasma levels during spontaneous migraine attacks relative to interictal PACAP38 plasma levels. Migraine sufferers also had lower interictal PACAP38 plasma levels compared with healthy controls. Another study reported elevated PACAP38 plasma levels during migraine attacks and found that subsequent sumatriptan administration was associated with a decrease in PACAP38 plasma levels [<xref ref-type="bibr" rid="CR82">82</xref>]. In contrast, pooled data analysis from two PACAP38 provocation studies found no pre-ictal phase increase in PACAP38 plasma levels in MO patients who experienced migraine-like attacks [<xref ref-type="bibr" rid="CR37">37</xref>]. The conflicting data could be explained by assay variation [<xref ref-type="bibr" rid="CR82">82</xref>&#x02013;<xref ref-type="bibr" rid="CR84">84</xref>] and differences in timing of measurements. It is also debatable whether peripheral plasma measurements reliably reflect cranial PACAP38 release and therefore the jugular vein might constitute a more precise site of collecting blood samples. It should be noted that one study reported no difference in extracranial and cranial CGRP plasma levels in healthy volunteers [<xref ref-type="bibr" rid="CR85">85</xref>]. In addition, two of the studies [<xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR82">82</xref>] included both MO patients and migraine with aura (MA) patients. Thus, a different PACAP-response cannot be excluded in MO patients compared with MA patients. For future human provocation studies, it would be interesting to measure PACAP38 plasma levels after sumatriptan administration when using PACAP38 or other pharmacological &#x0201c;triggers&#x0201d; such as CGRP and cilostazol. Here, it would be important to have a placebo-controlled design; otherwise, PACAP38 could possibly decrease spontaneously over the course of a migraine attack. The exact antimigraine mechanism of sumatriptan remains unknown; thus, it could be speculated that a reduction in PACAP38 plasma levels might play a role.</p></sec><sec id="Sec11"><title>Heterogeneity of the PACAP38 response in MO patients</title><p id="Par41">Human experimental studies have revealed a heterogeneous PACAP38 response in MO patients in that some develop migraine-like attacks while others do not (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). In a total of three PACAP38 provocation studies, 46 out of 66 (70%) MO patients experienced migraine-like attacks (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Giving this evidence, the question is whether susceptibility to migraine follows a fluctuating pattern. Indeed, two studies suggested that the likelihood of migraine attack development exhibits innate variations [<xref ref-type="bibr" rid="CR86">86</xref>, <xref ref-type="bibr" rid="CR87">87</xref>] &#x02013; suggesting a migraine threshold that varies over time. Thus, it raises the issue of whether PACAP38-induced migraine-like attacks can only be induced at certain points in a migraine susceptibility cycle. This seems questionable because a small PACAP38 dose-response pilot study found that PACAP-induced migraine-like attacks seem to be reproducible in MO patients [<xref ref-type="bibr" rid="CR26">26</xref>]. Furthermore, the large sample size of MO patients who developed migraine-like attacks after PACAP38 infusion (46 out of 66) deem it improbable that all 46 patients were in a migraine susceptible phase. To dissect this issue, MO patients with few attacks on a yearly basis should undergo PACAP38 provocation to clarify the importance of possible cyclic migraine induction variability. In relation to this, one provocation study [<xref ref-type="bibr" rid="CR88">88</xref>] found no relation between headache frequencies in MO patients and GTN-induced headache.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Overview of PACAP38 provocation studies in migraine without aura (MO) patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Reference</th><th>Study design</th><th>Number of MO patients who developed migraine-like attacks</th><th>Total number of MO patients</th><th>Major findings</th></tr></thead><tbody><tr><td>Schytz et al. [<xref ref-type="bibr" rid="CR29">29</xref>]</td><td>Double-blind crossover</td><td>7</td><td>12</td><td>PACAP38 induces migraine-like attacks</td></tr><tr><td>Amin et al. [<xref ref-type="bibr" rid="CR34">34</xref>]</td><td>Double-blind randomized</td><td>16</td><td>22</td><td>PACAP38-induced migraine is associated with sustained dilation of extracranial arteries</td></tr><tr><td>Amin et al. [<xref ref-type="bibr" rid="CR44">44</xref>]</td><td>Double-blind crossover</td><td>18</td><td>24</td><td>PACAP38-induced migraine-like attacks is associated with altered functional cerebral connectivity</td></tr><tr><td>Guo et al. [<xref ref-type="bibr" rid="CR49">49</xref>]</td><td>Double-blinded</td><td>23</td><td>32</td><td>PACAP38 induces premonitory symptoms</td></tr><tr><td>Guo et al. [<xref ref-type="bibr" rid="CR54">54</xref>]</td><td>Double-blinded</td><td>23</td><td>32</td><td>PACAP38 response is not associated with high family load or risk allele status</td></tr></tbody></table></table-wrap><fig id="Fig1"><label>Fig. 1</label><caption><p>Proportion (median and range) of patients who developed migraine-like attacks and of patients who did not develop migraine-like attacks after PACAP38 infusion [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR54">54</xref>]</p></caption><graphic xlink:href="10194_2017_821_Fig1_HTML" id="MO1"/></fig></p><p id="Par42">Future provocation reproducibility studies should also include a three-arm crossover design with subjects randomized to PACAP38; PACAP38; Placebo. This would permit blinded assessment of PACAP38 reproducibility while controlling for placebo response. Following this, phenotyping migraine sufferers in PACAP38 responders versus non-responders could be used to possibly predict efficacy of drugs targeting the PACAP38 molecule or its PAC<sub>1</sub> receptor. This would delineate PACAP38 as a reliable biomarker of the migraine. Future studies should also investigate whether blockade of PACAP38 or its PAC<sub>1</sub> receptor may prevent the migraine-inducing effects of PACAP38. Moreover, studies in MA and FHM patients are needed to cover the whole migraine spectrum with respect to PACAP38 provocation. The same need exists for PACAP38 provocation studies in cluster headache and tension-type headache patients.</p></sec><sec id="Sec12"><title>Magnetic resonance imaging</title><p id="Par43">Advanced brain imaging in human experimental models provides a unique opportunity to identify biomarkers specific to primary headaches. PACAP38 provocation studies have demonstrated neuronal and vascular changes taking place in the brains of migraine sufferers both ictally and interictally. For this reason, future studies should investigate whether PACAP38 or PAC<sub>1</sub> receptor blockade is able to prevent PACAP38-induced MMA dilation. If this proves to be the case, the question is whether blockage of MMA dilation co-occurs with blockage of PACAP38-induced migraine-like attacks. This would in particular be interesting in a population of migraine patients that have previously been stratified as PACAP38 responders.</p></sec><sec id="Sec13"><title>PACAP27 as pharmacological &#x0201c;trigger&#x0201d; of primary headaches</title><p id="Par44">The migraine-inducing effects of PACAP38 have been well-documented but to date no study has investigated the migraine-inducing effect of PACAP27. It is the less abundant bioactive form of the PACAP molecule, but displays similar affinity to the PAC<sub>1</sub> receptor as PACAP38 [<xref ref-type="bibr" rid="CR89">89</xref>]. Interestingly, the role of the 28-to-38 segment of the PACAP molecule seems to be important for two reasons. First, one study [<xref ref-type="bibr" rid="CR90">90</xref>] indicated that the 28-to-38 segment could possibly play a role for the BBB transporter to recognize and transport the PACAP molecule across the BBB. Secondly, PACAP38 has a half-life of less than 5&#x000a0;min in human plasma in vitro, while PACAP27 displays a relative lack of degradation [<xref ref-type="bibr" rid="CR91">91</xref>]. For these reasons, it would be relevant to investigate the response to PACAP27 provocation in migraine and cluster headache patients.</p></sec></sec><sec id="Sec14"><title>Conclusion</title><p id="Par45">Great advances have been made over the past decade in understanding the pathophysiology of migraine using PACAP38 as a pharmacological &#x0201c;trigger&#x0201d;. Knowledge acquired from these human experimental studies has shed light on the PACAP38 molecule or its PAC<sub>1</sub> receptor as potential therapeutic drug targets. Nonetheless, the PACAP38 migraine-specific mechanisms of action have not been fully clarified and its involvement in cluster headache and tension-type headache remains a subject for investigation. Future studies will seek to refine design and execution; thereby, paving the way to delineate biomarkers of primary headache disorders.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AC</term><def><p id="Par4">Adenylate cyclase</p></def></def-item><def-item><term>cAMP</term><def><p id="Par5">Cyclic adenosine monophosphate</p></def></def-item><def-item><term>CGRP</term><def><p id="Par6">Calcitonin gene-related peptide</p></def></def-item><def-item><term>fMRI</term><def><p id="Par7">Functional magnetic resonance imaging</p></def></def-item><def-item><term>GTN</term><def><p id="Par8">Glyceryl trinitrate</p></def></def-item><def-item><term>IHS</term><def><p id="Par9">International Headache Society</p></def></def-item><def-item><term>MA</term><def><p id="Par10">Migraine with aura</p></def></def-item><def-item><term>MCA</term><def><p id="Par11">Middle cerebral artery</p></def></def-item><def-item><term>MMA</term><def><p id="Par12">Middle meningeal artery</p></def></def-item><def-item><term>MO</term><def><p id="Par13">Migraine without aura</p></def></def-item><def-item><term>MRA</term><def><p id="Par14">Magnetic resonance angiography</p></def></def-item><def-item><term>PACAP</term><def><p id="Par15">Pituitary adenylate cyclase-activating polypeptide</p></def></def-item><def-item><term>RCTs</term><def><p id="Par16">Randomized clinical trials</p></def></def-item><def-item><term>STA</term><def><p id="Par17">Superficial temporal artery</p></def></def-item><def-item><term>TCD</term><def><p id="Par18">Transcranial Doppler</p></def></def-item><def-item><term>TNC</term><def><p id="Par19">Trigeminal nucleus caudalis</p></def></def-item><def-item><term>VIP</term><def><p id="Par20">Vasoactive intestinal polypeptide</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>No acknowledgements.</p><sec id="FPar1"><title>Funding</title><p id="Par46">Lundbeck Foundation (R155&#x02013;2014-171).</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p id="Par47">The data supporting the conclusions of this article are available in English in the databases of PubMed and <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link>. A search for original studies and randomized controlled trials published in English was performed. The search term used was &#x0201c;PACAP38 and primary headaches&#x0201d; and &#x0201c;PACAP38 and migraine&#x0201d;. Reference lists of identified articles were also searched for additional relevant papers.</p></sec></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>HA designed and performed the review, with the help of SG, ALHV, and MA. HA drafted the manuscript with the help of SG, LAHV, and MA. All authors read and approved the final manuscript.</p></notes><notes notes-type="COI-statement"><sec id="FPar3"><title>Ethics approval and consent to participate</title><p id="Par48">Not applicable</p></sec><sec id="FPar4"><title>Consent for publication</title><p id="Par49">Not applicable</p></sec><sec id="FPar5"><title>Competing interests</title><p id="Par50">Messoud Ashina is a consultant, speaker or scientific advisor for Allergan, Amgen, Alder, ATI, Eli Lilly, Novartis, and Teva, primary investigator for Amgen 20,120,178 (Phase 2), 20,120,295 (Phase 2), 20,130,255 (OLE), 20,120,297 (Phase 3), Alder ALD403-CLIN-001 (Phase 3), Amgen PAC1 20,150,308 (Phase 2a), and GM-11 gamma-Core-R trials, and reports grants from Lundbeck Foundation (R155&#x02013;2014-171). H&#x000e5;kan Ashina, Song Guo, and Anne Luise Haulund Vollesen have no conflicts of interest.</p></sec><sec id="FPar6"><title>Publisher&#x02019;s Note</title><p id="Par51">Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schytz</surname><given-names>HW</given-names></name><name><surname>Hargreaves</surname><given-names>R</given-names></name><name><surname>Ashina</surname><given-names>M</given-names></name></person-group><article-title>Challenges in developing drugs for primary headaches</article-title><source>Prog Neurobiol</source><year>2017</year><volume>152</volume><fpage>70</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.pneurobio.2015.12.005</pub-id><?supplied-pmid 26751129?><pub-id pub-id-type="pmid">26751129</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Vollesen ALH, Ashina M (2017) PACAP38: Emerging Drug Target in Migraine and Cluster Headache. Headache 57:Suppl 2:56&#x02013;63</mixed-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuka</surname><given-names>B</given-names></name><name><surname>Szab&#x000f3;</surname><given-names>N</given-names></name><name><surname>T&#x000f3;th</surname><given-names>E</given-names></name><etal/></person-group><article-title>Release of PACAP-38 in episodic cluster headache patients - an exploratory study</article-title><source>J Headache Pain</source><year>2016</year><volume>17</volume><fpage>69</fpage><pub-id pub-id-type="doi">10.1186/s10194-016-0660-7</pub-id><?supplied-pmid 27475101?><pub-id pub-id-type="pmid">27475101</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheward</surname><given-names>WJ</given-names></name><name><surname>Lutz</surname><given-names>EM</given-names></name><name><surname>Copp</surname><given-names>AJ</given-names></name><name><surname>Harmar</surname><given-names>AJ</given-names></name></person-group><article-title>Expression of PACAP, and PACAP type 1 (PAC1) receptor mRNA during development of the mouse embryo</article-title><source>Brain Res Dev Brain Res</source><year>1998</year><volume>109</volume><fpage>245</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1016/S0165-3806(98)00086-8</pub-id><?supplied-pmid 9729410?><pub-id pub-id-type="pmid">9729410</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyata</surname><given-names>A</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Dahl</surname><given-names>RD</given-names></name><etal/></person-group><article-title>Isolation of a neuropeptide corresponding to the N-terminal 27 residues of the pituitary adenylate cyclase activating polypeptide with 38 residues (PACAP38)</article-title><source>Biochem Biophys Res Commun</source><year>1990</year><volume>170</volume><fpage>643</fpage><lpage>648</lpage><pub-id pub-id-type="doi">10.1016/0006-291X(90)92140-U</pub-id><?supplied-pmid 2383262?><pub-id pub-id-type="pmid">2383262</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulder</surname><given-names>H</given-names></name><name><surname>Uddman</surname><given-names>R</given-names></name><name><surname>Moller</surname><given-names>K</given-names></name><etal/></person-group><article-title>Pituitary adenylate cyclase activating polypeptide expression in sensory neurons</article-title><source>Neuroscience</source><year>1994</year><volume>63</volume><fpage>307</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1016/0306-4522(94)90025-6</pub-id><?supplied-pmid 7898655?><pub-id pub-id-type="pmid">7898655</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uddman</surname><given-names>R</given-names></name><name><surname>Tajti</surname><given-names>J</given-names></name><name><surname>Hou</surname><given-names>M</given-names></name><name><surname>Sundler</surname><given-names>F</given-names></name><name><surname>Edvinsson</surname><given-names>L</given-names></name></person-group><article-title>Neuropeptide expression in the human trigeminal nucleus caudalis and in the cervical spinal cord C1 and C2</article-title><source>Cephalalgia</source><year>2002</year><volume>22</volume><fpage>112</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1046/j.1468-2982.2002.00324.x</pub-id><?supplied-pmid 11972578?><pub-id pub-id-type="pmid">11972578</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dun</surname><given-names>EC</given-names></name><name><surname>Huang</surname><given-names>RL</given-names></name><name><surname>Dun</surname><given-names>SL</given-names></name><etal/></person-group><article-title>Pituitary adenylate cyclase activating polypeptide-immunoreactivity in human spinal cord and dorsal root ganglia</article-title><source>Brain Res</source><year>1996</year><volume>721</volume><fpage>233</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.1016/0006-8993(96)00139-4</pub-id><?supplied-pmid 8793105?><pub-id pub-id-type="pmid">8793105</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uddman</surname><given-names>R</given-names></name><name><surname>Tajti</surname><given-names>J</given-names></name><name><surname>M&#x000f6;ller</surname><given-names>S</given-names></name><name><surname>Sundler</surname><given-names>F</given-names></name><name><surname>Edvinsson</surname><given-names>L</given-names></name></person-group><article-title>Neuronal messengers and peptide receptors in the human sphenopalatine and otic ganglia</article-title><source>Brain Res</source><year>1999</year><volume>826</volume><fpage>193</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1016/S0006-8993(99)01260-3</pub-id><?supplied-pmid 10224296?><pub-id pub-id-type="pmid">10224296</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghatei</surname><given-names>MA</given-names></name><name><surname>Takahashi</surname><given-names>K</given-names></name><name><surname>Suzuki</surname><given-names>Y</given-names></name><name><surname>Gardiner</surname><given-names>J</given-names></name><name><surname>Jones</surname><given-names>PM</given-names></name><name><surname>Bloom</surname><given-names>SR</given-names></name></person-group><article-title>Distribution, molecular characterization of pituitary adenylate cyclase activating polypeptide and its precursor encoding messenger RNA in human and rat tissues</article-title><source>J Endocrinol</source><year>1993</year><volume>136</volume><fpage>159</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1677/joe.0.1360159</pub-id><?supplied-pmid 8094091?><pub-id pub-id-type="pmid">8094091</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dickson</surname><given-names>L</given-names></name><name><surname>Finlayson</surname><given-names>K</given-names></name></person-group><article-title>VPAC and PAC receptors: from ligands to function</article-title><source>Pharmacol Ther</source><year>2009</year><volume>121</volume><fpage>294</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2008.11.006</pub-id><?supplied-pmid 19109992?><pub-id pub-id-type="pmid">19109992</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fahrenkrug</surname><given-names>J</given-names></name></person-group><article-title>PACAP--a multifacetted neuropeptide</article-title><source>Chronobiol Int</source><year>2006</year><volume>23</volume><fpage>53</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1080/07420520500464569</pub-id><?supplied-pmid 16687279?><pub-id pub-id-type="pmid">16687279</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knutsson</surname><given-names>M</given-names></name><name><surname>Edvinsson</surname><given-names>L</given-names></name></person-group><article-title>Distribution of mRNA for VIP and PACAP receptors in human cerebral arteries and cranial ganglia</article-title><source>Neuroreport</source><year>2002</year><volume>13</volume><fpage>507</fpage><lpage>509</lpage><pub-id pub-id-type="doi">10.1097/00001756-200203250-00030</pub-id><?supplied-pmid 11930171?><pub-id pub-id-type="pmid">11930171</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>KY</given-names></name><name><surname>Baun</surname><given-names>M</given-names></name><name><surname>De Vries</surname><given-names>R</given-names></name><etal/></person-group><article-title>Pharmacological characterization of VIP and PACAP receptors in the human meningeal and coronary artery</article-title><source>Cephalalgia</source><year>2011</year><volume>31</volume><fpage>181</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1177/0333102410375624</pub-id><?supplied-pmid 20974589?><pub-id pub-id-type="pmid">20974589</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vaudry</surname><given-names>D</given-names></name><name><surname>Gonzalez</surname><given-names>BJ</given-names></name><name><surname>Basille</surname><given-names>M</given-names></name><name><surname>Yon</surname><given-names>L</given-names></name><name><surname>Fournier</surname><given-names>A</given-names></name><name><surname>Vaudry</surname><given-names>H</given-names></name></person-group><article-title>Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions</article-title><source>Pharmacol Rev</source><year>2000</year><volume>52</volume><fpage>269</fpage><lpage>324</lpage><?supplied-pmid 10835102?><pub-id pub-id-type="pmid">10835102</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ottesen</surname><given-names>B</given-names></name><name><surname>Pedersen</surname><given-names>B</given-names></name><name><surname>Nielsen</surname><given-names>J</given-names></name><name><surname>Dalgaard</surname><given-names>D</given-names></name><name><surname>Wagner</surname><given-names>G</given-names></name><name><surname>Fahrenkrug</surname><given-names>J</given-names></name></person-group><article-title>Vasoactive intestinal polypeptide (VIP) provokes vaginal lubrication in normal women</article-title><source>Peptides</source><year>1987</year><volume>8</volume><fpage>797</fpage><lpage>800</lpage><pub-id pub-id-type="doi">10.1016/0196-9781(87)90061-1</pub-id><?supplied-pmid 3432128?><pub-id pub-id-type="pmid">3432128</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boni</surname><given-names>L</given-names></name><name><surname>Ploug</surname><given-names>K</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name><name><surname>Jansen-Olesen</surname><given-names>I</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name></person-group><article-title>The in vivo effect of VIP, PACAP-38 and PACAP-27 and mRNA expression of their receptors in rat middle meningeal artery</article-title><source>Cephalalgia</source><year>2009</year><volume>29</volume><fpage>837</fpage><lpage>847</lpage><pub-id pub-id-type="doi">10.1111/j.1468-2982.2008.01807.x</pub-id><?supplied-pmid 19220306?><pub-id pub-id-type="pmid">19220306</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kulka</surname><given-names>M</given-names></name><name><surname>Sheen</surname><given-names>CH</given-names></name><name><surname>Tancowny</surname><given-names>BP</given-names></name><name><surname>Grammer</surname><given-names>LC</given-names></name><name><surname>Schleimer</surname><given-names>RP</given-names></name></person-group><article-title>Neuropeptides activate human mast cell degranulation and chemokine production</article-title><source>Immunology</source><year>2008</year><volume>123</volume><fpage>398</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2567.2007.02705.x</pub-id><?supplied-pmid 17922833?><pub-id pub-id-type="pmid">17922833</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tajti</surname><given-names>J</given-names></name><name><surname>Tuka</surname><given-names>B</given-names></name><name><surname>Botz</surname><given-names>B</given-names></name><name><surname>Helyes</surname><given-names>Z</given-names></name><name><surname>Vecsei</surname><given-names>L</given-names></name></person-group><article-title>Role of pituitary adenylate cyclase-activating polypeptide in nociception and migraine</article-title><source>CNS Neurol Disord Drug Targets</source><year>2015</year><volume>14</volume><fpage>540</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.2174/1871527314666150429114234</pub-id><?supplied-pmid 25921738?><pub-id pub-id-type="pmid">25921738</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fahrenkrug</surname><given-names>J</given-names></name><name><surname>Hannibal</surname><given-names>J</given-names></name><name><surname>Tams</surname><given-names>J</given-names></name><name><surname>Georg</surname><given-names>B</given-names></name></person-group><article-title>Immunohistochemical localization of the VIP1 receptor (VPAC1R) in rat cerebral blood vessels: relation to PACAP and VIP containing nerves</article-title><source>J Cereb Blood Flow Metab</source><year>2000</year><volume>20</volume><fpage>1205</fpage><lpage>1214</lpage><pub-id pub-id-type="doi">10.1097/00004647-200008000-00006</pub-id><?supplied-pmid 10950381?><pub-id pub-id-type="pmid">10950381</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akerman</surname><given-names>S</given-names></name><name><surname>Goadsby</surname><given-names>PJ</given-names></name></person-group><article-title>Neuronal PAC1 receptors mediate delayed activation and sensitization of trigeminocervical neurons: relevance to migraine</article-title><source>Sci Transl med</source><year>2015</year><volume>7</volume><fpage>308ra157</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aaa7557</pub-id><?supplied-pmid 26446954?><pub-id pub-id-type="pmid">26446954</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Alder. Robust development pipeline [Internet]. 2017 [cited 2017 Aug 27]. <ext-link ext-link-type="uri" xlink:href="http://www.alderbio.com/therapeutics/pipeline/">http://www.alderbio.com/therapeutics/pipeline/</ext-link></mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Amgen. Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention. In ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). [cited 2017 August 27]: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03238781">https://clinicaltrials.gov/ct2/show/NCT03238781</ext-link></mixed-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birk</surname><given-names>S</given-names></name><name><surname>Sitarz</surname><given-names>JT</given-names></name><name><surname>Petersen</surname><given-names>KA</given-names></name><etal/></person-group><article-title>The effect of intravenous PACAP38 on cerebral hemodynamics in healthy volunteers</article-title><source>Regul Pept</source><year>2007</year><volume>140</volume><fpage>185</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1016/j.regpep.2006.12.010</pub-id><?supplied-pmid 17320198?><pub-id pub-id-type="pmid">17320198</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shayestagul</surname><given-names>NA</given-names></name><name><surname>Christensen</surname><given-names>CE</given-names></name><name><surname>Amin</surname><given-names>FM</given-names></name><etal/></person-group><article-title>Measurement of blood flow velocity in the middle cerebral artery during spontaneous migraine attacks: a systematic review</article-title><source>Headache</source><year>2017</year><volume>57</volume><fpage>852</fpage><lpage>861</lpage><pub-id pub-id-type="doi">10.1111/head.13106</pub-id><?supplied-pmid 28470726?><pub-id pub-id-type="pmid">28470726</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vollesen</surname><given-names>AL</given-names></name><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Ashina</surname><given-names>M</given-names></name></person-group><article-title>PACAP38 dose-response pilot study in migraine patients</article-title><source>Cephalalgia</source><year>2017</year><volume>37</volume><fpage>391</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1177/0333102416644435</pub-id><?supplied-pmid 27084887?><pub-id pub-id-type="pmid">27084887</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="other">Headache Classification Committee of the International Headache Society (IHS) (2013) The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia 33:629&#x02013;808</mixed-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name><name><surname>Ashina</surname><given-names>M</given-names></name></person-group><article-title>Phosphodiesterase 3 inhibitor cilostazol induces migraine-like attacks via cyclic AMP increase</article-title><source>Brain</source><year>2014</year><volume>137</volume><fpage>2951</fpage><lpage>2959</lpage><pub-id pub-id-type="doi">10.1093/brain/awu244</pub-id><?supplied-pmid 25161294?><pub-id pub-id-type="pmid">25161294</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schytz</surname><given-names>HW</given-names></name><name><surname>Birk</surname><given-names>S</given-names></name><name><surname>Wienecke</surname><given-names>T</given-names></name><name><surname>Kruuse</surname><given-names>C</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name><name><surname>Ashina</surname><given-names>M</given-names></name></person-group><article-title>PACAP38 induces migraine-like attacks in patients with migraine without aura</article-title><source>Brain</source><year>2009</year><volume>132</volume><fpage>16</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1093/brain/awn307</pub-id><?supplied-pmid 19052139?><pub-id pub-id-type="pmid">19052139</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansen</surname><given-names>JM</given-names></name><name><surname>Hauge</surname><given-names>AW</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name><name><surname>Ashina</surname><given-names>M</given-names></name></person-group><article-title>Calcitonin gene related peptide triggersmigraine-like attacks in patients with migraine with aura</article-title><source>Cephalalgia</source><year>2010</year><volume>30</volume><fpage>1179</fpage><lpage>1186</lpage><pub-id pub-id-type="doi">10.1177/0333102410368444</pub-id><?supplied-pmid 20855363?><pub-id pub-id-type="pmid">20855363</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomsen</surname><given-names>LL</given-names></name><name><surname>Kruuse</surname><given-names>C</given-names></name><name><surname>Iversen</surname><given-names>HK</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name></person-group><article-title>A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks</article-title><source>Eur J Neurol</source><year>1994</year><volume>1</volume><fpage>73</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1111/j.1468-1331.1994.tb00053.x</pub-id><?supplied-pmid 24283432?><pub-id pub-id-type="pmid">24283432</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amin</surname><given-names>FM</given-names></name><name><surname>Lundholm</surname><given-names>E</given-names></name><name><surname>Hougaard</surname><given-names>A</given-names></name><etal/></person-group><article-title>Measurement precision and biological variation of cranial arteries using automated analysis of 3 T magnetic resonance angiography</article-title><source>J Headache Pain</source><year>2014</year><volume>15</volume><fpage>25</fpage><pub-id pub-id-type="doi">10.1186/1129-2377-15-25</pub-id><?supplied-pmid 24886137?><pub-id pub-id-type="pmid">24886137</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amin</surname><given-names>FM</given-names></name><name><surname>Asghar</surname><given-names>MS</given-names></name><name><surname>Guo</surname><given-names>S</given-names></name><etal/></person-group><article-title>Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers</article-title><source>Cephalalgia</source><year>2012</year><volume>32</volume><fpage>140</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1177/0333102411431333</pub-id><?supplied-pmid 22174350?><pub-id pub-id-type="pmid">22174350</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amin</surname><given-names>FM</given-names></name><name><surname>Hougaard</surname><given-names>A</given-names></name><name><surname>Schytz</surname><given-names>HW</given-names></name><etal/></person-group><article-title>Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38</article-title><source>Brain</source><year>2014</year><volume>137</volume><fpage>779</fpage><lpage>794</lpage><pub-id pub-id-type="doi">10.1093/brain/awt369</pub-id><?supplied-pmid 24501094?><pub-id pub-id-type="pmid">24501094</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asghar</surname><given-names>MS</given-names></name><name><surname>Hansen</surname><given-names>AE</given-names></name><name><surname>Kapijimpanga</surname><given-names>T</given-names></name><etal/></person-group><article-title>Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers</article-title><source>Neurology</source><year>2010</year><volume>75</volume><fpage>1520</fpage><lpage>1526</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181f9626a</pub-id><?supplied-pmid 20975053?><pub-id pub-id-type="pmid">20975053</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="other">Grande G, Nilsson E, Edvinsson L Comparison of responses to vasoactive drugs in human and rat cerebral arteries using myography and pressurized cerebral artery method. Cephalalgia 33:152&#x02013;159</mixed-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Humphrey</surname><given-names>PP</given-names></name><name><surname>Feniuk</surname><given-names>W</given-names></name></person-group><article-title>Mode of action of the anti-migraine drug sumatriptan</article-title><source>Trends Pharmacol Sci</source><year>1991</year><volume>12</volume><fpage>444</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1016/0165-6147(91)90630-B</pub-id><?supplied-pmid 1665260?><pub-id pub-id-type="pmid">1665260</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benemei</surname><given-names>S</given-names></name><name><surname>Cortese</surname><given-names>F</given-names></name><name><surname>Labastida-Ram&#x000ed;rez</surname><given-names>A</given-names></name><etal/></person-group><article-title>Triptans and CGRP blockade - impact on the cranial vasculature</article-title><source>J Headache Pain</source><year>2017</year><volume>18</volume><fpage>103</fpage><pub-id pub-id-type="doi">10.1186/s10194-017-0811-5</pub-id><?supplied-pmid 29019093?><pub-id pub-id-type="pmid">29019093</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amin</surname><given-names>FM</given-names></name><name><surname>Asghar</surname><given-names>MS</given-names></name><name><surname>Ravneberg</surname><given-names>JW</given-names></name><etal/></person-group><article-title>The effect of sumatriptan on cephalic arteries: a 3T MR-angiography study in healthy volunteers</article-title><source>Cephalalgia</source><year>2013</year><volume>33</volume><fpage>1009</fpage><lpage>1016</lpage><pub-id pub-id-type="doi">10.1177/0333102413483374</pub-id><?supplied-pmid 23588794?><pub-id pub-id-type="pmid">23588794</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asghar</surname><given-names>MS</given-names></name><name><surname>Hansen</surname><given-names>AE</given-names></name><name><surname>Amin</surname><given-names>FM</given-names></name><etal/></person-group><article-title>Evidence for a vascular factor in migraine</article-title><source>Ann Neurol</source><year>2011</year><volume>69</volume><fpage>635</fpage><lpage>645</lpage><pub-id pub-id-type="doi">10.1002/ana.22292</pub-id><?supplied-pmid 21416486?><pub-id pub-id-type="pmid">21416486</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harmar</surname><given-names>AJ</given-names></name><name><surname>Arimura</surname><given-names>A</given-names></name><name><surname>Gozes</surname><given-names>I</given-names></name><etal/></person-group><article-title>International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide</article-title><source>Pharmacol Rev</source><year>1998</year><volume>50</volume><fpage>265</fpage><lpage>270</lpage><?supplied-pmid 9647867?><pub-id pub-id-type="pmid">9647867</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahmann</surname><given-names>A</given-names></name><name><surname>Wienecke</surname><given-names>T</given-names></name><name><surname>Hansen</surname><given-names>JM</given-names></name><name><surname>Fahrenkrug</surname><given-names>J</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name><name><surname>Ashina</surname><given-names>M</given-names></name></person-group><article-title>Vasoactive intestinal peptide causes marked cephalic vasodilation, but does not induce migraine</article-title><source>Cephalalgia</source><year>2008</year><volume>28</volume><fpage>226</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1111/j.1468-2982.2007.01497.x</pub-id><?supplied-pmid 18254893?><pub-id pub-id-type="pmid">18254893</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Vollesen</surname><given-names>ALH</given-names></name><name><surname>Hansen</surname><given-names>YB</given-names></name><etal/></person-group><article-title>Part II: biochemical changes after pituitary adenylate cyclase-activating polypeptide-38 infusion in migraine patients</article-title><source>Cephalalgia</source><year>2017</year><volume>37</volume><fpage>136</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1177/0333102416639517</pub-id><?supplied-pmid 26994298?><pub-id pub-id-type="pmid">26994298</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amin</surname><given-names>FM</given-names></name><name><surname>Hougaard</surname><given-names>A</given-names></name><name><surname>Magon</surname><given-names>S</given-names></name><etal/></person-group><article-title>Change in brain network connectivity during PACAP38-induced migraine attacks: a resting-state functional MRI study</article-title><source>Neurology</source><year>2016</year><volume>86</volume><fpage>180</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000002261</pub-id><?supplied-pmid 26674334?><pub-id pub-id-type="pmid">26674334</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seeley</surname><given-names>WW</given-names></name><name><surname>Menon</surname><given-names>V</given-names></name><name><surname>Schatzberg</surname><given-names>AF</given-names></name><etal/></person-group><article-title>Dissociable intrinsic connectivity networks for salience processing and executive control</article-title><source>J Neurosci</source><year>2007</year><volume>27</volume><fpage>2349</fpage><lpage>2356</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.5587-06.2007</pub-id><?supplied-pmid 17329432?><pub-id pub-id-type="pmid">17329432</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buckner</surname><given-names>RL</given-names></name><name><surname>Andrews-Hanna</surname><given-names>JR</given-names></name><name><surname>Schacter</surname><given-names>DL</given-names></name></person-group><article-title>The brain&#x02019;s default network: anatomy, function, and relevance to disease</article-title><source>Ann N Y Acad Sci</source><year>2008</year><volume>1124</volume><fpage>1</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1196/annals.1440.011</pub-id><?supplied-pmid 18400922?><pub-id pub-id-type="pmid">18400922</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindquist</surname><given-names>KA</given-names></name><name><surname>Wager</surname><given-names>TD</given-names></name><name><surname>Kober</surname><given-names>H</given-names></name><name><surname>Bliss-Moreau</surname><given-names>E</given-names></name><name><surname>Barrett</surname><given-names>LF</given-names></name></person-group><article-title>The brain basis of emotion: a meta-analytic review</article-title><source>Behav Brain Sci</source><year>2012</year><volume>35</volume><fpage>121</fpage><lpage>143</lpage><pub-id pub-id-type="doi">10.1017/S0140525X11000446</pub-id><?supplied-pmid 22617651?><pub-id pub-id-type="pmid">22617651</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peyron</surname><given-names>R</given-names></name><name><surname>Laurent</surname><given-names>B</given-names></name><name><surname>Garc&#x00131;a-Larrea</surname><given-names>L</given-names></name></person-group><article-title>Functional imaging of brain responses to pain. A review and meta-analysis</article-title><source>Neurophysiol Clin Neurophysiol</source><year>2000</year><volume>30</volume><fpage>263</fpage><lpage>288</lpage><pub-id pub-id-type="doi">10.1016/S0987-7053(00)00227-6</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Haulund Vollesen</surname><given-names>AL</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name><name><surname>Ashina</surname><given-names>M</given-names></name></person-group><article-title>Premonitory and non-headache symptoms induced by CGRP and PACAP38 in migraine patients</article-title><source>Pain</source><year>2016</year><volume>157</volume><fpage>2773</fpage><lpage>2781</lpage><pub-id pub-id-type="doi">10.1097/j.pain.0000000000000702</pub-id><?supplied-pmid 27842045?><pub-id pub-id-type="pmid">27842045</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Afridi</surname><given-names>SK</given-names></name><name><surname>Kaube</surname><given-names>H</given-names></name><name><surname>Goadsby</surname><given-names>PJ</given-names></name></person-group><article-title>Glyceryl trinitrate triggers premonitory symptoms in migraineurs</article-title><source>Pain</source><year>2004</year><volume>110</volume><fpage>675</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2004.05.007</pub-id><?supplied-pmid 15288408?><pub-id pub-id-type="pmid">15288408</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lucas</surname><given-names>RN</given-names></name></person-group><article-title>Migraine in twins</article-title><source>J Psychosom Res</source><year>1977</year><volume>21</volume><fpage>147</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1016/0022-3999(77)90082-4</pub-id><?supplied-pmid 859128?><pub-id pub-id-type="pmid">859128</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ziegler</surname><given-names>DK</given-names></name><name><surname>Hur</surname><given-names>YM</given-names></name><name><surname>Bouchard</surname><given-names>TJ</given-names></name><name><surname>Hassanein</surname><given-names>RS</given-names></name><name><surname>Barter</surname><given-names>R</given-names></name></person-group><article-title>Migraine in twins raised together and apart</article-title><source>Headache</source><year>1998</year><volume>38</volume><fpage>417</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.1046/j.1526-4610.1998.3806417.x</pub-id><?supplied-pmid 9664744?><pub-id pub-id-type="pmid">9664744</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gervil</surname><given-names>M</given-names></name><name><surname>Ulrich</surname><given-names>V</given-names></name><name><surname>Kyvik</surname><given-names>KO</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name><name><surname>Russell</surname><given-names>MB</given-names></name></person-group><article-title>Migraine without aura: a population-based twin study</article-title><source>Ann Neurol</source><year>1999</year><volume>46</volume><fpage>606</fpage><lpage>611</lpage><pub-id pub-id-type="doi">10.1002/1531-8249(199910)46:4&#x0003c;606::AID-ANA8&#x0003e;3.0.CO;2-O</pub-id><?supplied-pmid 10514097?><pub-id pub-id-type="pmid">10514097</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Vollesen</surname><given-names>ALH</given-names></name><name><surname>Hansen</surname><given-names>RD</given-names></name><etal/></person-group><article-title>Part I: pituitary adenylate cyclase-activating polypeptide-38 induced migraine-like attacks in patients with and without familial aggregation of migraine</article-title><source>Cephalalgia</source><year>2017</year><volume>37</volume><fpage>125</fpage><lpage>135</lpage><pub-id pub-id-type="doi">10.1177/0333102416639516</pub-id><?supplied-pmid 26994299?><pub-id pub-id-type="pmid">26994299</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birk</surname><given-names>S</given-names></name><name><surname>Kruuse</surname><given-names>C</given-names></name><name><surname>Petersen</surname><given-names>KA</given-names></name><name><surname>Jonassen</surname><given-names>O</given-names></name><name><surname>Tfelt-Hansen</surname><given-names>P</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name></person-group><article-title>The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow</article-title><source>J Cereb Blood Flow Metab</source><year>2004</year><volume>24</volume><fpage>1352</fpage><lpage>1358</lpage><pub-id pub-id-type="doi">10.1097/01.WCB.0000143536.22131.D7</pub-id><?supplied-pmid 15625409?><pub-id pub-id-type="pmid">15625409</pub-id></element-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hogan</surname><given-names>AD</given-names></name><name><surname>Schwartz</surname><given-names>LB</given-names></name></person-group><article-title>Markers of mast cell degranulation</article-title><source>Methods</source><year>1997</year><volume>13</volume><fpage>43</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1006/meth.1997.0494</pub-id><?supplied-pmid 9281467?><pub-id pub-id-type="pmid">9281467</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lassen</surname><given-names>LH</given-names></name><name><surname>Thomsen</surname><given-names>LL</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name></person-group><article-title>Histamine induces migraine via the H1-receptor. Support for the NO hypothesis of migraine</article-title><source>Neuroreport</source><year>1995</year><volume>6</volume><fpage>1475</fpage><lpage>1479</lpage><pub-id pub-id-type="doi">10.1097/00001756-199507310-00003</pub-id><?supplied-pmid 7579128?><pub-id pub-id-type="pmid">7579128</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baun</surname><given-names>M</given-names></name><name><surname>Pedersen</surname><given-names>MHF</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name><name><surname>Jansen-Olesen</surname><given-names>I</given-names></name></person-group><article-title>Dural mast cell degranulation is a putative mechanism for headache induced by PACAP-38</article-title><source>Cephalalgia</source><year>2012</year><volume>32</volume><fpage>337</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1177/0333102412439354</pub-id><?supplied-pmid 22421901?><pub-id pub-id-type="pmid">22421901</pub-id></element-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhatt</surname><given-names>DK</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name><name><surname>Jansen-Olesen</surname><given-names>I</given-names></name></person-group><article-title>PACAP-38 infusion causes sustained vasodilation of the middle meningeal artery in the rat: possible involvement of mast cells</article-title><source>Cephalalgia</source><year>2014</year><volume>34</volume><fpage>877</fpage><lpage>886</lpage><pub-id pub-id-type="doi">10.1177/0333102414523846</pub-id><?supplied-pmid 24563332?><pub-id pub-id-type="pmid">24563332</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>D</given-names></name><name><surname>Burstein</surname><given-names>R</given-names></name><name><surname>Kainz</surname><given-names>V</given-names></name><name><surname>Jakubowski</surname><given-names>M</given-names></name><name><surname>Strassman</surname><given-names>AM</given-names></name></person-group><article-title>Mast cell degranulation activates a pain pathway underlying migraine headache</article-title><source>Pain</source><year>2007</year><volume>130</volume><fpage>166</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1016/j.pain.2007.03.012</pub-id><?supplied-pmid 17459586?><pub-id pub-id-type="pmid">17459586</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><mixed-citation publication-type="other">Uddman R, Luts A, Arimura A, Sundler F (1991) Pituitary adenylate cyclase-activating peptide (PACAP), a new vasoactive intestinal peptide (VIP)-like peptide in the respiratory tract. Cell Tissue Res 265:197&#x02013;201</mixed-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moller</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>YZ</given-names></name><name><surname>H&#x000e5;kanson</surname><given-names>R</given-names></name><etal/></person-group><article-title>Pituitary adenylate cyclase activating peptide is a sensory neuropeptide: immunocytochemical and immunochemical evidence</article-title><source>Neuroscience</source><year>1993</year><volume>57</volume><fpage>725</fpage><lpage>732</lpage><pub-id pub-id-type="doi">10.1016/0306-4522(93)90018-B</pub-id><?supplied-pmid 7508577?><pub-id pub-id-type="pmid">7508577</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goadsby</surname><given-names>PJ</given-names></name></person-group><article-title>New directions in migraine research</article-title><source>J Clin Neurosci</source><year>2002</year><volume>9</volume><fpage>368</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1054/jocn.2001.0967</pub-id><?supplied-pmid 12217664?><pub-id pub-id-type="pmid">12217664</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edvinsson</surname><given-names>L</given-names></name><name><surname>Hara</surname><given-names>H</given-names></name><name><surname>Uddman</surname><given-names>R</given-names></name></person-group><article-title>Retrograde tracing of nerve fibers to the rat middle cerebral artery with true blue: colocalization with different peptides</article-title><source>J Cereb Blood Flow Metab</source><year>1989</year><volume>9</volume><fpage>212</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1038/jcbfm.1989.31</pub-id><?supplied-pmid 2466041?><pub-id pub-id-type="pmid">2466041</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uddman</surname><given-names>R</given-names></name><name><surname>Hara</surname><given-names>H</given-names></name><name><surname>Edvinsson</surname><given-names>L</given-names></name></person-group><article-title>Neuronal pathways to the rat middle meningeal artery revealed by retrograde tracing and immunocytochemistry</article-title><source>J Auton Nerv Syst</source><year>1989</year><volume>26</volume><fpage>69</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/0165-1838(89)90109-4</pub-id><?supplied-pmid 2785130?><pub-id pub-id-type="pmid">2785130</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eftekhari</surname><given-names>S</given-names></name><name><surname>Warfvinge</surname><given-names>K</given-names></name><name><surname>Blixt</surname><given-names>FW</given-names></name><name><surname>Edvinsson</surname><given-names>L</given-names></name></person-group><article-title>Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system</article-title><source>J Pain</source><year>2013</year><volume>14</volume><fpage>1289</fpage><lpage>1303</lpage><pub-id pub-id-type="doi">10.1016/j.jpain.2013.03.010</pub-id><?supplied-pmid 23958278?><pub-id pub-id-type="pmid">23958278</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shioda</surname><given-names>S</given-names></name><name><surname>Shuto</surname><given-names>Y</given-names></name><name><surname>Somogyvari-Vigh</surname><given-names>A</given-names></name><etal/></person-group><article-title>Localization and gene expression of the receptor for pituitary adenylate cyclase-activating polypeptide in the rat brain</article-title><source>Neurosci Res</source><year>1997</year><volume>28</volume><fpage>345</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1016/S0168-0102(97)00065-5</pub-id><?supplied-pmid 9274830?><pub-id pub-id-type="pmid">9274830</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schytz</surname><given-names>HW</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name><name><surname>Ashina</surname><given-names>M</given-names></name></person-group><article-title>The PACAP receptor: a novel target for migraine treatment</article-title><source>Neurotherapeutics</source><year>2010</year><volume>7</volume><fpage>191</fpage><lpage>196</lpage><pub-id pub-id-type="doi">10.1016/j.nurt.2010.02.003</pub-id><?supplied-pmid 20430318?><pub-id pub-id-type="pmid">20430318</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jansen-Olesen</surname><given-names>I</given-names></name><name><surname>Mortensen</surname><given-names>A</given-names></name><name><surname>Edvinsson</surname><given-names>L</given-names></name></person-group><article-title>Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilatation of human cerebral arteries concomitant with activation of adenylyl cyclase</article-title><source>Cephalalgia</source><year>1996</year><volume>16</volume><fpage>310</fpage><lpage>316</lpage><pub-id pub-id-type="doi">10.1046/j.1468-2982.1996.1605310.x</pub-id><?supplied-pmid 8869765?><pub-id pub-id-type="pmid">8869765</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Shakur</surname><given-names>Y</given-names></name><name><surname>Yoshitake</surname><given-names>M</given-names></name><name><surname>Kambayashi Ji</surname><given-names>J</given-names></name></person-group><article-title>Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake</article-title><source>Cardiovasc Drug Rev</source><year>2001</year><volume>19</volume><fpage>369</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1111/j.1527-3466.2001.tb00076.x</pub-id><?supplied-pmid 11830753?><pub-id pub-id-type="pmid">11830753</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lassen</surname><given-names>LH</given-names></name><name><surname>Haderslev</surname><given-names>PA</given-names></name><name><surname>Jacobsen</surname><given-names>VB</given-names></name><name><surname>Iversen</surname><given-names>HK</given-names></name><name><surname>Sperling</surname><given-names>B</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name></person-group><article-title>CGRP may play a causative role in migraine</article-title><source>Cephalalgia</source><year>2002</year><volume>22</volume><fpage>54</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1046/j.1468-2982.2002.00310.x</pub-id><?supplied-pmid 11993614?><pub-id pub-id-type="pmid">11993614</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ingram</surname><given-names>SL</given-names></name><name><surname>Williams</surname><given-names>JT</given-names></name></person-group><article-title>Modulation of the hyperpolarization-activated current (Ih) by cyclic nucleotides in guinea-pig primary afferent neurons</article-title><source>J Physiol</source><year>1996</year><volume>492</volume><fpage>97</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.1996.sp021292</pub-id><?supplied-pmid 8730586?><pub-id pub-id-type="pmid">8730586</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strassman</surname><given-names>AM</given-names></name><name><surname>Raymond</surname><given-names>SA</given-names></name><name><surname>Burstein</surname><given-names>R</given-names></name></person-group><article-title>Sensitization of meningeal sensory neurons and the origin of headaches</article-title><source>Nature</source><year>1996</year><volume>384</volume><fpage>560</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1038/384560a0</pub-id><?supplied-pmid 8955268?><pub-id pub-id-type="pmid">8955268</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><mixed-citation publication-type="other">Amgen. To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients. In ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000-[cited 2017 October 18] Available from: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02542605">https://clinicaltrials.gov/ct2/show/NCT02542605</ext-link></mixed-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banks</surname><given-names>WA</given-names></name><name><surname>Uchida</surname><given-names>D</given-names></name><name><surname>Arimura</surname><given-names>A</given-names></name><name><surname>Somogyv&#x000e1;ri-Vigh</surname><given-names>A</given-names></name><name><surname>Shioda</surname><given-names>S</given-names></name></person-group><article-title>Transport of pituitary adenylate cyclase-activating polypeptide across the blood-brain barrier and the prevention of ischemia-induced death of hippocampal neurons</article-title><source>Ann N Y Acad Sci</source><year>1996</year><volume>805</volume><fpage>270</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.1996.tb17489.x</pub-id><?supplied-pmid 8993409?><pub-id pub-id-type="pmid">8993409</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dogrukol-Ak</surname><given-names>D</given-names></name><name><surname>Tore</surname><given-names>F</given-names></name><name><surname>Tuncel</surname><given-names>N</given-names></name></person-group><article-title>Passage of VIP/PACAP/secretin family across the blood-brain barrier: therapeutic effects</article-title><source>Curr Pharm Des</source><year>2004</year><volume>10</volume><fpage>1325</fpage><lpage>1340</lpage><pub-id pub-id-type="doi">10.2174/1381612043384934</pub-id><?supplied-pmid 15134484?><pub-id pub-id-type="pmid">15134484</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>H</given-names></name><name><surname>Shintani</surname><given-names>N</given-names></name><name><surname>Baba</surname><given-names>A</given-names></name></person-group><article-title>New insights into the central PACAPergic system from the phenotypes in PACAP- and PACAP receptor-knockout mice</article-title><source>Ann N Y Acad Sci</source><year>2006</year><volume>1070</volume><fpage>75</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1196/annals.1317.038</pub-id><?supplied-pmid 16888150?><pub-id pub-id-type="pmid">16888150</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Malmberg</surname><given-names>AB</given-names></name><name><surname>Yaksh</surname><given-names>TL</given-names></name><name><surname>Sj&#x000f6;lund</surname><given-names>B</given-names></name><name><surname>Sundler</surname><given-names>F</given-names></name><name><surname>H&#x000e5;kanson</surname><given-names>R</given-names></name></person-group><article-title>Capsaicin-evoked release of pituitary adenylate cyclase activating peptide (PACAP) and calcitonin gene-related peptide (CGRP) from rat spinal cord in vivo</article-title><source>Regul Pept</source><year>1997</year><volume>69</volume><fpage>83</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/S0167-0115(97)02133-2</pub-id><?supplied-pmid 9178350?><pub-id pub-id-type="pmid">9178350</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arimura</surname><given-names>A</given-names></name><name><surname>Somogyvari-Vigh</surname><given-names>A</given-names></name><name><surname>Miyata</surname><given-names>A</given-names></name><name><surname>Mizuno</surname><given-names>K</given-names></name><name><surname>Coy</surname><given-names>DH</given-names></name><name><surname>Kitada</surname><given-names>C</given-names></name></person-group><article-title>Tissue distribution of PACAP as determined by RIA: highly abundant in the rat brain and testes</article-title><source>Endocrinology</source><year>1991</year><volume>129</volume><fpage>2787</fpage><lpage>2789</lpage><pub-id pub-id-type="doi">10.1210/endo-129-5-2787</pub-id><?supplied-pmid 1935809?><pub-id pub-id-type="pmid">1935809</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maniyar</surname><given-names>FH</given-names></name><name><surname>Sprenger</surname><given-names>T</given-names></name><name><surname>Monteith</surname><given-names>T</given-names></name><name><surname>Schankin</surname><given-names>C</given-names></name><name><surname>Goadsby</surname><given-names>PJ</given-names></name></person-group><article-title>Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks</article-title><source>Brain</source><year>2014</year><volume>137</volume><fpage>232</fpage><lpage>241</lpage><pub-id pub-id-type="doi">10.1093/brain/awt320</pub-id><?supplied-pmid 24277718?><pub-id pub-id-type="pmid">24277718</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuka</surname><given-names>B</given-names></name><name><surname>Helyes</surname><given-names>Z</given-names></name><name><surname>Markovics</surname><given-names>A</given-names></name><etal/></person-group><article-title>Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients</article-title><source>Cephalalgia</source><year>2013</year><volume>33</volume><fpage>1085</fpage><lpage>1095</lpage><pub-id pub-id-type="doi">10.1177/0333102413483931</pub-id><?supplied-pmid 23598374?><pub-id pub-id-type="pmid">23598374</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zagami</surname><given-names>AS</given-names></name><name><surname>Edvinsson</surname><given-names>L</given-names></name><name><surname>Goadsby</surname><given-names>PJ</given-names></name></person-group><article-title>Pituitary adenylate cyclase activating polypeptide and migraine</article-title><source>Ann Clin Transl Neurol</source><year>2014</year><volume>1</volume><fpage>1036</fpage><lpage>1040</lpage><pub-id pub-id-type="doi">10.1002/acn3.113</pub-id><?supplied-pmid 25574477?><pub-id pub-id-type="pmid">25574477</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jakab</surname><given-names>B</given-names></name><name><surname>Reglodi</surname><given-names>D</given-names></name><name><surname>Jozsa</surname><given-names>R</given-names></name><etal/></person-group><article-title>Distribution of PACAP-38 in the central nervous system of various species determined by a novel radioimmunoassay</article-title><source>J Biochem Biophys Methods</source><year>2004</year><volume>61</volume><fpage>189</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.1016/j.jbbm.2004.03.002</pub-id><?supplied-pmid 15560935?><pub-id pub-id-type="pmid">15560935</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hannibal</surname><given-names>J</given-names></name><name><surname>Mikkelsen</surname><given-names>JD</given-names></name><name><surname>Clausen</surname><given-names>H</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name><name><surname>Wulff</surname><given-names>BS</given-names></name><name><surname>Fahrenkrug</surname><given-names>J</given-names></name></person-group><article-title>Gene expression of pituitary adenylate cyclase activating polypeptide (PACAP) in the rat hypothalamus</article-title><source>Regul Pept</source><year>1995</year><volume>55</volume><fpage>133</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1016/0167-0115(94)00099-J</pub-id><?supplied-pmid 7754101?><pub-id pub-id-type="pmid">7754101</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashina</surname><given-names>M</given-names></name><name><surname>Bendtsen</surname><given-names>L</given-names></name><name><surname>Jensen</surname><given-names>R</given-names></name><name><surname>Schifter</surname><given-names>S</given-names></name><name><surname>Jansen-Olesen</surname><given-names>I</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name></person-group><article-title>Plasma levels of calcitonin gene-related peptide in chronic tension-type headache</article-title><source>Neurology</source><year>2000</year><volume>55</volume><fpage>1335</fpage><lpage>1340</lpage><pub-id pub-id-type="doi">10.1212/WNL.55.9.1335</pub-id><?supplied-pmid 11087777?><pub-id pub-id-type="pmid">11087777</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stankewitz</surname><given-names>A</given-names></name><name><surname>May</surname><given-names>A</given-names></name></person-group><article-title>Increased limbic and brainstem activity during migraine attacks following olfactory stimulation</article-title><source>Neurology</source><year>2011</year><volume>77</volume><fpage>476</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e318227e4a8</pub-id><?supplied-pmid 21775739?><pub-id pub-id-type="pmid">21775739</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulte</surname><given-names>LH</given-names></name><name><surname>May</surname><given-names>A</given-names></name></person-group><article-title>The migraine generator revisited: continuous scanning of the migraine cycle over 30 days and three spontaneous attacks</article-title><source>Brain</source><year>2016</year><volume>139</volume><fpage>1987</fpage><lpage>1993</lpage><pub-id pub-id-type="doi">10.1093/brain/aww097</pub-id><?supplied-pmid 27190019?><pub-id pub-id-type="pmid">27190019</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Christiansen</surname><given-names>I</given-names></name><name><surname>Daugaard</surname><given-names>D</given-names></name><name><surname>Lykke Thomsen</surname><given-names>L</given-names></name><name><surname>Olesen</surname><given-names>J</given-names></name></person-group><article-title>Glyceryl trinitrate induced headache in migraineurs - relation to attack frequency</article-title><source>Eur J Neurol</source><year>2000</year><volume>7</volume><fpage>405</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1046/j.1468-1331.2000.00094.x</pub-id><?supplied-pmid 10971600?><pub-id pub-id-type="pmid">10971600</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cauvin</surname><given-names>A</given-names></name><name><surname>Buscail</surname><given-names>L</given-names></name><name><surname>Gourlet</surname><given-names>P</given-names></name><etal/></person-group><article-title>The novel VIP-like hypothalamic polypeptide PACAP interacts with high affinity receptors in the human neuroblastoma cell line NB-OK</article-title><source>Peptides</source><year>1990</year><volume>11</volume><fpage>773</fpage><lpage>777</lpage><pub-id pub-id-type="doi">10.1016/0196-9781(90)90194-A</pub-id><?supplied-pmid 2172943?><pub-id pub-id-type="pmid">2172943</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Banks</surname><given-names>WA</given-names></name><name><surname>Kastin</surname><given-names>AJ</given-names></name><name><surname>Komaki</surname><given-names>G</given-names></name><name><surname>Arimura</surname><given-names>A</given-names></name></person-group><article-title>Pituitary adenylate cyclase activating polypeptide (PACAP) can cross the vascular component of the blood-testis barrier in the mouse</article-title><source>J Androl</source><year>1993</year><volume>14</volume><fpage>170</fpage><lpage>173</lpage><?supplied-pmid 8407571?><pub-id pub-id-type="pmid">8407571</pub-id></element-citation></ref><ref id="CR91"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bourgault</surname><given-names>S</given-names></name><name><surname>Vaudry</surname><given-names>D</given-names></name><name><surname>Botia</surname><given-names>B</given-names></name><etal/></person-group><article-title>Novel stable PACAP analogs with potent activity towards the PAC1 receptor</article-title><source>Peptides</source><year>2008</year><volume>29</volume><fpage>919</fpage><lpage>932</lpage><pub-id pub-id-type="doi">10.1016/j.peptides.2008.01.022</pub-id><?supplied-pmid 18353507?><pub-id pub-id-type="pmid">18353507</pub-id></element-citation></ref></ref-list></back></article>